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Abstract
Although most bacteraemic outcome studies have focused on mortality, a repeated episode(s) is another important outcome of bacter-
aemia. We sought to characterize patient factors and microbial species associated with recurrence and death from bacteraemia. Popula-
tion-based surveillance for bacteraemia was conducted in a Canadian health region during 2000–2008. Episodes of bacteraemia were
extracted and characterized. Transition intensities of both recurrence and death were estimated by separate multivariate Cox propor-
tional hazards models. We identiﬁed 9713 patients with incident episodes of bacteraemia. Within 1 year: 892 (9.2%) had recurrent bac-
teraemia, 2401 (24.7%) had died without a recurrent episode and 330 (3.4%) had died after a recurrent episode. Independent risk
factors for recurrence within 1 year (hazard ratio; 95% conﬁdence interval) were: increasing Charlson comorbidity scores (score 1–2:
2.2; 1.8–2.7 and score 3+: 3.4; 2.8–4.2), origin of infection (nosocomial: 2.1; 1.8–2.6 and healthcare-associated: 2.4; 2.0–2.8), microorgan-
ism (polymicrobial: 1.5; 1.2–2.0 and fungal: 2.8; 1.9–4.2) and focus of infection (veriﬁed urogenital: 0.4; 0.3–0.6). Independent risk factors
for death within 1 year included: a recurrent bacteraemic episode 3.6 (3.1–4.0), increasing age and different foci of infection. This study
identiﬁes patient groups at risk of having a recurrent episode and dying from these infections. It adds recurrent bacteraemia as an inde-
pendent risk factor of death within 1 year and may help to target patients for prevention or changes in management.
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Introduction
Bacteraemia is a leading cause worldwide of morbidity and
mortality [1]. Bacteraemic outcome studies have focused on
predictors of mortality, and factors predisposing individuals
to bacteraemia are well described in many different settings
[2–4]. However, a repeated bacteraemic episode(s), after sur-
viving the primary infection, is another important outcome.
Several previous hospital-based studies have investigated this
entity and found that recurrence rates range between 2%
and 17%, and that mortality is not higher [5–9]. These stud-
ies are limited by the inclusion of highly selected patients or
microorganisms and so may not be widely generalizable.
Population-based surveillance is widely recognized as an
optimal means for establishing the epidemiology of an infec-
tious disease. To our knowledge there are only two popula-
tion-based studies that have investigated recurrent
bacteraemia. The ﬁrst comprised 8672 adults in Denmark
with incident bacteraemia; it reported a rate of recurrence
of 12% and identiﬁed the main risk factors for recurrence as:
bacteraemia that was healthcare-associated or nosocomial;
polymicrobial bacteraemia or fungaemia; patients with Charl-
son comorbidity index scores of ‡1; an infectious focus
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either unknown or in the gastrointestinal tract or liver/biliary
tract, endocarditis, or related to an intravenous catheter
[10]. Another recent study, of Gram-negative bloodstream
infections from the United States in 944 adults and children,
found recurrence rates after 1, 5 and 10 years of 6%, 9%
and 15%, respectively [11].
There is a limited body of literature reporting on the epi-
demiology of recurrent bacteraemia in non-selected popula-
tions and reports from other jurisdictions are needed. The
objectives of this study were to determine (i) the incidence
of all recurrent bacteraemias occurring in a large, non-
selected population in Canada, and (ii) independent risk fac-
tors for both recurrence and death.
Methods
Study population
The Calgary Zone of Alberta Health Services provides all
publicly funded medical and surgical care to the residents
of the cities of Calgary and Airdrie and a large surrounding
area (population 1.2 million) in the Province of Alberta,
Canada. Only patients requiring liver, heart or lung trans-
plantation surgery are routinely referred elsewhere for
care. All persons who resided in the Calgary Zone and
who developed a bacteraemic infection during 2000–2007
were included.
The Conjoint Health Research Ethics Board at the Univer-
sity of Calgary approved this study and waived the require-
ment for individual written informed consent.
Study protocol
We used an active, population-based surveillance cohort
design. All data were obtained using the Electronic Surveil-
lance System (ESS) [12]. This database contains all patients
with bacteraemia in the Calgary Zone and has been devel-
oped through a linkage between the regional and provincial
microbiology, hospital, disease registry and vital statistics
databases. Demographic, microbiological and mortality
outcome data are available for all patients and further infor-
mation on comorbidities are available for those admitted to
any of the main regional acute-care centres.
Deﬁnitions
The Electronic Surveillance System deﬁnes an episode of bac-
teraemia as growth of pathogenic bacteria or fungus from at
least one aerobic/anaerobic set of blood culture bottles; for
common skin contaminants including diphtheroids, Bacillus
spp., Propionibacterium spp., coagulase-negative staphylococci,
viridans group streptococci and micrococci, isolation of the
organism from at least two different blood samples within a
5-day period was required to fulﬁl the criteria for bacteraemia
[13]. Performance of blood culture was at the discretion of
the attending medical team and was not dictated by study
protocol.
We deﬁned an incident episode of bacteraemia by isola-
tion of one or more clinically important pathogens within a
48-h period. Re-isolation of the same species within 30 days
was considered to be from the same episode [10,14–16].
Recurrent episodes of bacteraemia were those where a dif-
ferent species was isolated more than 48 h after the index
episode or the same species was isolated more than 30 days
after the index episode. The incident non-recurrent episodes
and the incident recurrent episodes refer to the initial bacte-
raemic episode with or without later recurrence, respec-
tively. The second bacteraemic episode is referred to as the
recurrent episode.
Polymicrobial bacteraemia was deﬁned as an episode with
more than one clinically important blood culture isolate
detected within 48 h [15].
Nosocomial bacteraemias were those with incident posi-
tive culture collected ‡48 h after hospital admission or
within 48 h of discharge. Community-onset infections were
those where incident positive culture was obtained within
48 h of admission or >48 h after discharge from hospital
[17]. Community-onset bacteraemias were further classiﬁed
as community-acquired or healthcare-associated according to
a modiﬁcation of the deﬁnitions of Friedman et al. [12,18].
The focus of infection was based on microbiological ﬁndings
from other sites within 48-h of the drawing of the blood cul-
ture. Comorbidities were determined and Charlson score
was calculated using discharge data by application of a previ-
ously validated algorithm [19,20].
Statistical analyses
We pursued two different analysis strategies. The focus of the
ﬁrst analysis was the separate evaluation of covariate effects
on both recurrence and death (before recurrence). To that
extent, transition intensities (cause-speciﬁc hazards) for both
recurrence and death were estimated by separate multivariate
Cox proportional hazards models (Fig. 1). The second analysis
modelled covariate effects on mortality in a multivariate Cox
proportional hazards model where recurrence was included
as a time-dependent covariate. The following prognostic fac-
tors (at incident bacteraemia) were considered for modelling
the (separate) cause-speciﬁc hazards (Table 1): age (categories:
0–8, 19–64, 65–79, 80+ years), Charlson comorbidity index
(categorized: 0, 1–2, 3+, unknown), sex, origin of infection
(categories: community-acquired, nosocomial, healthcare-asso-
ciated), microorganism(s) (monomicrobial Gram-positive, mo-
CMI Jensen et al. Competing outcomes of bacteraemia 1149
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1148–1154
nomicrobial Gram-negative, monomicrobial anaerobic, polymi-
crobial, fungal and unknown) and focus (unveriﬁed, veriﬁed
urogenital (UG), veriﬁed non-UG and multifocal). The esti-
mated effects of prognostic factors were expressed as hazard
ratios (HRs) and reported with 95% CI. As a consequence of
the missing values, 20 observations were excluded from the
Cox regression analysis, leaving 9693 patients with incident
bacteraemia—890 with recurrent bacteraemia. Statistical anal-
yses were performed using STATA (version 11.1/SE; Stata-
Corp, College Station, TX, USA).
Results
During 2000–2007, a total of 9713 patients had incident epi-
sodes of bloodstream infection; 892 (9%) had recurrent epi-
sodes within 1 year. The baseline characteristics of patients
with incident episodes of bacteraemia are displayed in
Table 1. The median age of the patients was 62 years (inter-
quartile range, 43–76 years) with no signiﬁcant difference
between the incident episodes with no later recurrence and
the incident episodes that later recurred.
Recurrent episodes were found in 834 adult patients and
58 children (<18 years). Of the 892 patients who experi-
enced recurrence before death within 1 year, 95 (11%), 204
(23%), 528 (59%), 710 (80%) and 804 (90%) had a recurrent
episode within 10, 30, 90, 180 and 270 days, respectively.
Monomicrobial bacteraemia accounted for 8268 (94%) of
the incident episodes with no later recurrence, 813 (91%) of
the incident episodes that later recurred and 819 (92%) of
the recurrent episodes, respectively. The proportion of fun-
gaemia was higher in recurrent episodes (6%) compared with
incident episodes that later recurred (3%) and incident epi-
sodes with no later recurrence (1%), respectively. Incident
episodes with no later recurrence displayed more monomi-
crobial Gram-negative isolates compared with incident epi-
sodes that later recurred. Incident episodes that later
recurred displayed more monomicrobial anaerobic isolates
compared with recurrent episodes, but fewer monomicrobial
Gram-positive isolates. In 751 patients (84%) both episodes
were monomicrobial, and the same microorganism was
retrieved in both episodes in 273 patients (273/751, 36%).
Among these 273 paired episodes the most frequent
microorganisms were Staphylococcus aureus (90/273, 33%),
TABLE 1. Baseline characteristics
of patients with incident episodes
of bacteraemia
Prognostic factor n %
Age (at incident bacteraemia) 0–18a 935 10
19–64 4210 43
65–79 2727 28
80+ 1837 19
Unknown/missing 4 (excluded) 0
Charlson comorbidity
index (at incident bacteraemia)
0a 3250 33
1–2 2907 30
3+ 2278 23
Unknown/missing 1278 (separate category) 13
Sex Femalea 4452 46
Male 5259 54
Unknown/missing 2 (excluded) 0
Origin of infection
(at incident bacteraemia)
Community-acquireda 4370 45
Nosocomial 2344 24
Healthcare-associated 2999 31
Microorganism(s)
(at incident bacteraemia)
Monomicrobial Gram-negativea 3825 39
Monomicrobial Gram-positive 4591 47
Monomicrobial anaerobic 501 5
Polymicrobial 632 7
Fungal 150 2
Unknown/missing 14 (excluded) 0
Focus of infection
(at incident bacteraemia)
Unveriﬁeda 6990 72
Veriﬁed UG 1583 16
Veriﬁed non-UG 1005 10
Multifocal 135 1
In all, 892 patients had recurrent bacteraemia within 1 year, 2401 patients died before experiencing recurrence and
330 patients died after recurrence (within 1 year).
UG, urogenital.
aRefers to reference category.
Transition1–2: 890 events
Transition 1–3: 2401 events Transition 2–3: 330 events
Initial stage 1:
incident bacteraemia 
n = 9693   
Intermediate stage 2: 
recurrent bacteraemia  
n = 890   
Absorbing stage 3: death 
FIG. 1. Unidirectional illness–death model for
transition intensities; all transitions censored
at 1 year from initial stage.
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coagulase-negative staphylococci (66/273, 24%) and Escherichi-
a coli (55/273, 20%).
A number of selected conditions were identiﬁed as pre-
dictors for acquiring a recurrent episode within 1 year, and
these are shown in Table 2. Healthcare-associated bactera-
emia, Charlson comorbidity index score of ‡ 3 and funga-
emia were the most important predictors. Among 29
patients with recurrence and fungaemia at the incident epi-
sode, Candida albicans was the most prevalent microorgan-
ism, accounting for 38% of the episodes, followed by Candida
glabrata (35%). The remaining eight episodes were the result
of the following microorganisms: Candida kefyr, Candida kru-
sei, Candida parapsilosis, Candida tropicalis, Cryptococcus neofor-
mans and Saccharomyces cerevisiae. Monomicrobial anaerobic
bacteraemia and a veriﬁed UG focus of infection lowered
the risks of recurrence in relation to the reference category.
Sex and age of the patient were not important predictors of
recurrence.
In the Cox regression analysis for mortality (Table 3), we
found increasing age and increasing Charlson comorbidity
index score to be important predictors of death. Also, fac-
tors regarding the origin of infection, the focus of infection
and the microorganisms involved were independent predic-
tors for death. A veriﬁed UG focus of infection had a lower
risk of death than the reference category.
Adding recurrence as a time-dependent variable to the
Cox regression analysis for mortality did not change the haz-
ard ratios of the different prognostic factors notably. But,
having experienced a recurrent episode of bacteraemia was
also a strong independent predictor for death within 1 year
(Table 4).
Discussion
In this article, we report novel population-based data
describing the recurrence rates and risk factors for recur-
rence and death of bacteraemia in a large Canadian popula-
tion. We found that 9% of patients with bacteraemia
experienced a recurrence, of which 59% occurred within
3 months. Similar ﬁndings have been reported in the two
contemporary studies investigating the epidemiology of
recurrent bacteraemia in non-selected populations—Jensen
et al. [10] and Al-Hasan et al. [11] (Gram-negative bactera-
emia)—with which we were able to make a comparison.
Our results are also in accordance with the greater num-
ber of non-population-based studies. Studies of Miller and
Farr [21], and Capdevila et al. [22] found recurrent bactera-
emia rates of 10% and 9%, respectively. Wendt et al. [23],
and Mylotte and McDermott [24] both reported recurrence
rates in patients with recurrent Gram-negative bacteraemia
comparable with ours (13% and 10%, respectively). Others
have studied recurrences only in selected pathogens
[5–8,25,26]. Deﬁnitions of recurrence and follow-up periods
differ among these studies. Our follow up of 1 year was
identical to that used by Jensen et al. [10], but most previous
studies [5,22–24] applied short follow-up periods, albeit 3-
months or even 10 years of follow up have also been applied
[11,25,26]. Unfortunately, no gold standard to determine the
follow-up period exists. What determines the optimal fol-
low-up period is probably the weight of factors that may sig-
niﬁcantly change the longevity of the host such as
comorbidity and extreme age. Therefore, differences in
TABLE 2. Risks of recurrent bac-
teraemia within 1 year in 9693
patients with bacteraemia (890
events)
Prognostic factor HR (95% CI) p-value
Age (at incident bacteraemia) 0–18a 1
19–64 1.30 (0.98–1.72) 0.069
65–79 1.35 (1.01–1.81) 0.044
80– 0.97 (0.70–1.35) 0.867
Charlson comorbidity
index (at incident bacteraemia)
0a 1
1–2 2.17 (1.77–2.65) <0.001
3+ 3.40 (2.77–4.19) <0.001
Unknown/missing 2.61 (2.06–3.30) <0.001
Sex Femalea 1
Male 1.11 (0.97–1.27) 0.132
Origin of infection
(at incident bacteraemia)
Community-acquireda 1
Nosocomial 2.14 (1.77–2.59) <0.001
Healthcare-associated 2.37 (2.00–2.80) <0.001
Microorganism(s)
(at incident bacteraemia)
Monomicrobial Gram-negativea 1
Monomicrobial Gram-positive 1.17 (1.00–1.38) 0.049
Monomicrobial anaerobic 0.53 (0.24–0.83) 0.005
Polymicrobial 1.52 (1.18–1.97) 0.001
Fungal 2.82 (1.90–4.18) <0.001
Focus of infection
(at incident bacteraemia)
Unveriﬁeda 1
Veriﬁed UG 0.43 (0.33–0.56) <0.001
Veriﬁed non-UG 0.97 (0.79–1.20) 0.799
Multifocal 1.28 (0.78–2.10) 0.337
HR, hazard ratio; CI, conﬁdence interval; UG, urogenital.
aRefers to reference category.
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terminology and follow-up periods may inﬂuence the recur-
rence rates.
Different studies have shown that patients with serious
underlying conditions are at greater risk of recurrence.
Recurrent Streptococcus pneumoniae and Gram-negative bac-
teraemia have been associated with immune deﬁciency
caused by, for example, cancer, congenital B-cell or T-cell
defects, and human immunodeﬁciency virus infection [5,24].
Jensen et al. [10] found a Charlson comorbidity index score
of ‡ 1 and a focus of infection in the abdomen, endocarditis,
or an unknown focus to be independent risk factors of
recurrence. They also described characteristics of the micro-
biological ﬁndings and the iatrogenic factors as important
predictors of recurrent episodes. Our current data support
these ﬁndings. We identiﬁed several patient and microorgan-
ism characteristics as well as the iatrogenic factor as inde-
pendent risk factors of recurrent bacteraemia (Table 2). For
example, a patient with a nosocomial origin, an unveriﬁed
focus of infection and a Charlson score of 1–2 had a more
than tenfold increased HR for recurrent bacteraemia com-
pared with a patient with a community-acquired origin, a
veriﬁed UG focus of infection and a Charlson score of 0.
Previous population-based studies of bacteraemia have
identiﬁed advancing age, comorbidities, focus of infection
TABLE 3. Risks of mortality with-
out recurrence within 1 year in
9693 patients with bacteraemia
(2398 events)
Prognostic factor HR (95% CI) p-value
Age (at incident bacteraemia) 0–18a 1
19–64 1.59 (1.21–2.10) 0.001
65–79 2.74 (2.08–3.60) <0.001
80– 4.24 (3.22–5.59) <0.001
Charlson comorbidity
index (at incident bacteraemia)
0a 1
1–2 2.76 (2.40–3.18) <0.001
3+ 5.27 (4.58–6.06) <0.001
Unknown/missing 1.46 (1.18–1.80) <0.001
Sex Femalea 1
Male 0.97 (0.89–1.05) 0.431
Origin of infection
(at incident bacteraemia)
Community-acquireda 1
Nosocomial 2.12 (1.90–2.38) <0.001
Healthcare-associated 1.79 (1.61–2.00) <0.001
Microorganism(s)
(at incident bacteraemia)
Monomicrobial Gram-negativea 1
Monomicrobial Gram-positive 0.95 (0.86–1.04) 0.276
Monomicrobial anaerobic 1.37 (1.16–1.63) <0.001
Polymicrobial 1.29 (1.11–1.50) 0.001
Fungal 1.66 (1.29–2.13) <0.001
Focus of infection
(at incident bacteraemia)
Unveriﬁeda 1
Veriﬁed UG 0.61 (0.54–0.70) <0.001
Veriﬁed non-UG 1.28 (1.13–1.45) <0.001
Multifocal 1.62 (1.23–2.15) 0.001
HR, hazard ratio; CI, conﬁdence interval; UG, urogenital.
aRefers to reference category.
TABLE 4. Risks of mortality within
1 year with recurrence as time-
dependent variable in 9693
patients with bacteraemia (2728
events)
Prognostic factor HR (95% CI) p-value
Age (at incident bacteraemia) 0–18a 1
19–64 1.54 (1.21–1.96) <0.001
65–79 2.58 (2.02–3.28) <0.001
80– 3.91 (3.07–4.99) <0.001
Charlson comorbidity
index (at incident bacteraemia)
0a 1
1–2 2.70 (2.36–3.08) <0.001
3+ 4.96 (4.35–5.66) <0.001
Unknown/missing 1.45 (1.19–1.76) <0.001
Sex Femalea 1
Male 0.98 (0.91–1.06) 0.586
Origin of infection
(at incident bacteraemia)
Community-acquireda 1
Nosocomial 2.04 (1.83–2.28) <0.001
Healthcare-associated 1.81 (1.63–2.01) <0.001
Microorganism(s)
(at incident bacteraemia)
Monomicrobial Gram-negativea 1
Monomicrobial Gram-positive 0.93 (0.83–1.02) 0.116
Monomicrobial anaerobic 1.31 (1.11–1.54) 0.001
Polymicrobial 1.27 (1.10–1.47) 0.001
Fungal 1.48 (1.17–1.86) 0.001
Focus of infection
(at incident bacteraemia)
Unveriﬁeda 1
Veriﬁed UG 0.61 (0.54–0.70) <0.001
Veriﬁed non-UG 1.26 (1.12–1.42) <0.001
Multifocal 1.46 (1.12–1.91) 0.005
Recurrent bacteraemia Within 1 year 3.55 (3.13–4.02) <0.001
HR, hazard ratio; CI, conﬁdence interval; UG, urogenital.
aRefers to reference category.
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other than UG, polymicrobial infection, nosocomial acquisi-
tion and inappropriate empirical antibiotic treatment as being
associated with death [16,27,28]. Similar results have been
documented in a few contemporary population-based studies
of bacteraemia attributed to one speciﬁc microorganism
[4,29,30]. Our observation of risk factors of death within
1 year compares with (the trends of) the adjusted ORs of
30-day case fatality found by Pedersen et al. [16], the
adjusted 30-day Mortality Rate Ratios found by Søgaard et al.
[28] and the adjusted 180-day Mortality Rate Ratios found by
Hanon et al. [27] as well as the adjusted ORs of in-hospital
death found in the studies of bacteraemia attributed to one
speciﬁc microorganism [4,29,30]. Moreover, our present
study is important in that we add recurrent bacteraemia as a
strong independent risk factor (HR 3.6; 95% CI 3.1–4.0) of
death within 1 year (Table 4).
Though we did not investigate incidence rates in this
study, recent population-based studies of bacteraemia have
estimated incidence rates of bacteraemia to be between 125
per 100 000 person-years in Finland [31] to 156 per 100 000
person-years in females and 237 per 100 000 person-years in
males in Olmsted County, MN [32]. From Northern Den-
mark, Søgaard et al. [33] recently reported an increase of
the overall annual incidence rate of 46%, from 114 to 166
episodes per 100 000 person-years from 1992 to 2006. In
Calgary, Canada, Laupland et al. [34] compared incidence and
in-hospital case fatality of community-acquired bacteraemia
(82/100 000; 13%) with incidence and in-hospital case fatality
after trauma (70/100 000; 12%), after myocardial infarction
(161/100 000; 9%) and after stroke (150/100 000; 13%) dur-
ing 2000–2004.
Our study has several characteristics that make its results
robust. The study had a population-based design with public
hospitals accounting for >99% of all hospital admissions. In
addition, our cohort was much larger than those of ‘‘selected
population’’ studies (341–1205 patients). Finally, we used a
strict set of deﬁnitions and ensured almost complete follow
up with the exception of Charlson comorbidity index scores.
Although a rigorous population-based design was used,
there are some study limitations that merit discussion. Only
patients who had a positive blood culture were included in
this study. Patients who may have had bacteraemia but from
whom no sample was submitted for culture would not have
been identiﬁed in this study. The rates presented should
therefore be viewed as conservative estimates of all true
bacteraemias in the population studied. Another limitation is
that each patient was not clinically assessed to determine a
potential focus of infection; this was based, crudely, on the
presence of positive cultures from other sites. Therefore,
we were not able to elucidate to what extend reduction in
the rates of, for example, catheter-related bacteraemias had
occurred [35]. Third, no clinical information was available to
evaluate the clinical state of the patients at the time of
admission or the development of any clinical complications
such as septic shock, disseminated intravascular coagulation,
renal failure, or respiratory failure in connection with the
incident bacteraemic episode. Finally, data on antimicrobial
chemotherapy and details of dosing as well as timing of and
duration of therapy were not available. This is potentially a
major factor in determining recurrence and certainly in
determining mortality.
Future research should include detailed information on
antimicrobial chemotherapy (timing of the empirical treat-
ment, dosage regimens and duration of therapy) to extend
our understanding of predictors of recurrent bacteraemia as
well as predictors of death.
In summary, this study conﬁrms the major burden of
recurrence and mortality associated with bacteraemia and
identiﬁes patient-groups at increased risk of having a recur-
rent episode and dying from these infections. This study also
adds recurrent bacteraemia as an independent risk factor of
death within 1 year.
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